<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374205</url>
  </required_header>
  <id_info>
    <org_study_id>01KA22062006</org_study_id>
    <nct_id>NCT00374205</nct_id>
  </id_info>
  <brief_title>Randomized Trial on Effectiveness of ACTs in Ghana</brief_title>
  <official_title>A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bernhard Nocht Institute for Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Presbyterian Health Service (PHS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kumasi Centre for Collaborative Research (KCCR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>School of Medical Sciences Kumasi (SMS/KNUST)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bernhard Nocht Institute for Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of two Artemisinin
      Combination Therapies (ACTs) for the treatment of children with uncomplicated Plasmodium
      falciparum malaria
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Childhood mortality related to Plasmodium falciparum malaria is on the rise with more than 1
      million deaths per year in Sub-Saharan Africa. In the context of growing drug-resistance to
      antimalarials health officials are calling for rapid replacement of failing drugs by
      combining antimalarial drugs. Artemisinin Combination Antimalarial Therapies (ACTs) are in
      the focus of malaria control programmes and are recommended for first-line treatment in
      African countries. ACTs have been reported to be highly effective as artemisinin derivatives
      cause a rapid and substantial decrease in the parasite load when used for treating patients
      with malaria and resistance to artemisinin is still lacking. However, the short half-lives of
      artemisinins result in frequent recrudescent infections when used alone and therefore, much
      interest lays on the choice of the combination partner drug. ACTs also have been proposed as
      a means of reducing transmission by the reduction of gametocytes and of delaying the spread
      of drug resistance and prolonging the therapeutic life span of. Nevertheless, drug resistance
      of parasites to the respective partner drug is a matter of concern. Artesunate-amodiaquine
      (AQ) and artemether-lumefantrine (AL) are two registered fixed-dose artemisinin combination
      chemotherapies used in Africa which are GMP-manufactured at industrial scale. There is still
      limited data from randomised, controlled trials to support the general effectiveness of these
      two ACTs in Africa, including Ghana. More data is needed to compare these two therapies to
      make evidence-based first-line treatment decisions. Importantly, it is difficult to predict
      how combination therapy may affect the spread of drug resistance and monitoring drug
      resistance markers should be embedded in these trials to guide drug policy decision.

      The aim of this open-labelled, randomised drug trial is to compare the effectiveness and
      safety of artesunate-amodiaquine (Arsucam®) against artemether plus lumefantrine (Coartem®)
      for the treatment of children under five years of age with uncomplicated Plasmodium
      falciparum malaria.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis showed more LCFs in one of the treatment arms
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and PCR-controlled parasitological cure rate at day 28</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and PCR-controlled parasitological cure rate at day 14</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on anaemia</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular Drug Resistance Markers</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recrudescence and Reinfection</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Gametocytemia</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptance of Therapies</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of malaria episodes over a follow-up period of 1 year</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>AL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemether plus Lumefantrine 6 dose 3 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASAQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artesunate plus Amodiaquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate plus Amodiaquine</intervention_name>
    <description>Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer</description>
    <arm_group_label>ASAQ</arm_group_label>
    <other_name>Arsucam®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-Lumefantrine</intervention_name>
    <description>Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer</description>
    <arm_group_label>AL</arm_group_label>
    <other_name>Coartem®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female outpatients aged 6 months to 59 months

          -  Absence of severe malnutrition

          -  A slide-confirmed P. falciparum asexual parasitaemia between 2,000/µl and 200,000/µl

          -  A measured axillary temperature ≥ 37.5 °C or rectal/tympanic temperature ≥ 38.0 °C

          -  Absence of general danger signs (unable to drink; repeated vomiting; recent history of
             convulsions; lethargic or unconscious state; unable to stand up or to sit)

          -  Ability to tolerate oral therapy

          -  Permanent residence in study area

          -  Informed consent by the legal representative of the subject, if possible, the parents

        Exclusion Criteria:

          -  Adequate anti-malarial treatment within the previous 7 days

          -  Antibiotic treatment for a current infection

          -  Previous participation in a clinical trial

          -  Haemoglobin &lt; 5 g/dl

          -  Leucocyte count: &gt; 15000/µl

          -  Mixed plasmodial infection

          -  Severe malaria as defined by WHO recommendations

          -  Any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition,
             known HIV infection) or concomitant disease masking assessment of response

          -  History of allergy or intolerance against trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Ansong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medical Science (SMS), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Agogo Presbyterian Hospital</name>
      <address>
        <city>Agogo</city>
        <state>Asante Akim North District</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <link>
    <url>http://www15.bni-hamburg.de/bni/bni2/neu2/getfile.acgi?area_engl=researchgroups&amp;pid=2133</url>
    <description>Homepage of the Research Group Infection Epidemiology (co-ordination)</description>
  </link>
  <reference>
    <citation>Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006 May;1(1):e7. Epub 2006 May 19.</citation>
    <PMID>16871329</PMID>
  </reference>
  <reference>
    <citation>Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005 Apr 23-29;365(9469):1474-80.</citation>
    <PMID>15850631</PMID>
  </reference>
  <reference>
    <citation>Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P, De Palacios PI. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg. 2006 Jun;74(6):991-8.</citation>
    <PMID>16760509</PMID>
  </reference>
  <reference>
    <citation>Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006 Jun 1;42(11):1570-7. Epub 2006 Apr 26.</citation>
    <PMID>16652314</PMID>
  </reference>
  <reference>
    <citation>Mårtensson A, Strömberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Björkman A. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005 Oct 15;41(8):1079-86. Epub 2005 Sep 13.</citation>
    <PMID>16163624</PMID>
  </reference>
  <reference>
    <citation>Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis. 2006 Aug 15;194(4):528-35. Epub 2006 Jul 11.</citation>
    <PMID>16845638</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2006</study_first_submitted>
  <study_first_submitted_qc>September 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2006</study_first_posted>
  <last_update_submitted>November 26, 2007</last_update_submitted>
  <last_update_submitted_qc>November 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2007</last_update_posted>
  <keyword>Ghana</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <keyword>Drug-Resistance</keyword>
  <keyword>ACT</keyword>
  <keyword>Coartem</keyword>
  <keyword>Arsucam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

